Enhancing hepatitis C care engagement in the Netherlands: The road to micro-elimination

In chapter 2, it was demonstrated that in 2016 several second-generation ribavirin-free DAA regimens achieved viral eradication in ≥95% in different type of patients other than those with prior NS5A-inhibitor exposure or decompensated cirrhosis. In chapter 3, various patient-reported outcomes (PROs) were prospectively evaluated before, during and after DAA treatment. Ribavirin use was the only independent predictor of the transient decline in the mental health-related quality of life (HRQL) that occurred at the end of treatment (EOT). Twelve weeks after the end of treatment (FU12), the HRQL ha... Mehr ...